Case number 1:19-cv-01594
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Annora Pharma Private Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 10, 2020 | N/A | Terminated Case (0) Docket Text: CASES CLOSED per the entry of the Consent Judgment in Lead Case No. 18-1689-CFC. Associated Cases: 1:18-cv-01786-CFC-SRF, 1:19-cv-01594-CFC, 1:20-cv-00277-CFC(nmf) |
| Sep 11, 2019 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:18-cv-01689-CFC-SRF. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC ONLY. (nmf) |
| Sep 11, 2019 | 9 | SO ORDERED (12) Docket Text: SO ORDERED, re (83 in 1:18-cv-01689-CFC-SRF, 9 in 1:19-cv-01499-CFC, 8 in 1:19-cv-01498-CFC, 8 in 1:19-cv-01494-CFC, 7 in 1:19-cv-01492-CFC, 8 in 1:19-cv-01495-CFC, 8 in 1:19-cv-01501-CFC, 8 in 1:19-cv-01596-CFC, 9 in 1:19-cv-01500-CFC, 9 in 1:19-cv-01493-CFC, 8 in 1:19-cv-01594-CFC, 8 in 1:19-cv-01497-CFC, 7 in 1:19-cv-01496-CFC) STIPULATION Stipulation and [Proposed] Order for Consolidation. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC. Plaintiffs and Defendants shall follow the Scheduling Order entered in the Consolidated Action except for those deadlines outlined in this order. Signed by Judge Colm F. Connolly on 9/9/2019. Associated Cases: 1:18-cv-01689-CFC-SRF et al.(nmf) |
| Sep 4, 2019 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:19-cv-01594-CFC, 1:19-cv-01596-CFC (rjb) |
| Aug 30, 2019 | 6 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH. Hetero USA Inc. served on 8/29/2019, answer due 9/19/2019. (Egan, Brian) |
| Aug 30, 2019 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH. Annora Pharma Private Limited served on 8/29/2019, answer due 9/19/2019. (Egan, Brian) |
| Aug 30, 2019 | 8 | Stipulation (12) Docket Text: STIPULATION Stipulation and [Proposed] Order for Consolidation by Cipla Limited, Cipla USA, Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries, Inc., Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Phillips, John) |
| Aug 28, 2019 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Annora Pharma Private Limited and Hetero USA Inc. on 8/28/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (mal) |
| Aug 28, 2019 | 1 | Exhibit 1 (48) |
| Aug 28, 2019 | 1 | Civil Cover Sheet (2) |
| Aug 28, 2019 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Aug 28, 2019 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/20/2019. Date of Expiration of Patent: 04/03/2034.Thirty Month Stay Deadline: 2/1/2022. (mal) |
| Aug 28, 2019 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,258,637 B2. (mal) |
| Aug 28, 2019 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG. for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals Inc.. (mal) |
| Aug 28, 2019 | 1 | Complaint* (1) |
